The FDA flagged at least five cases of severe or very severe RSV lower respiratory tract infections in infants immunized with ...

A briefing document from the Food and Drug Administration (FDA) says that enrollment for all clinical studies of vaccines for ...

Ahead of an advisory committee meeting later this week, the FDA revealed that all studies for RSV vaccines in young children ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/91.DyCR3BqR.js ...

MinterEllison has advised Moderna in relation to its new mRNA manufacturing facility – a facility described by the firm as ...

When asked whether his fourth Senate term would be his last, Sanders (I-Vt.) said: “I’m 83 now. I’ll be 89 when I get out of ...

Along with holiday arrangements, changing seasons signal the need for another type of preparation: vaccination.

Once operational in 2025 (subject to regulatory approval), the facility will produce up to 100 million vaccine doses annually ...

Analysts issued an Underperform rating for shares while reluanching coverage of large-cap U.S. pharma and biotech names.

GSK plc stock is downgraded due to litigation risks, weak sales, and market pressures, dividend yield remains a bright spot. Click for more on GSK stock.

CRIS Healthy Aging will host vaccine clinics for those 60 and older, or people with disabilities aged 18-59, through the Aging and Disability Vaccination Collaborative, powered by USAging. The first ...

mRESVIA is Moderna's second approved product in Canada, the first mRNA vaccine against RSV, and the only one in single-dose pre-filled syringes Canada is the fourth jurisdiction to approve mRESVIA ...